Meet our researchers

Professor Martin K Oehler

Senior Research Associate at Department of Gynaecological Oncology, Royal Adelaide Hospital

Professor Martin K. Oehler is Director of Gynaecological Oncology at the Royal Adelaide Hospital and Clinical Professor in the Discipline of Obstetrics and Gynaecology at the University of Adelaide.

He qualified as gynaecologist in Germany and completed his subspecialty training as gynaecological oncologist at Westmead Hospital in Sydney and Monash Medical Centre in Melbourne.

Professor Oehler did a PhD in molecular biology and his extensive research experience includes previous appointments at the Department of Obstetrics & Gynaecology, Baylor College of Medicine, Houston/Texas, USA and the Institute of Molecular Medicine, University of Oxford, UK. He has a special interest in the basic science of ovarian cancer and is the Program Leader for Gynaecological Cancer Research, Robinson Institute, Research Centre for Reproductive Health, University of Adelaide.

Professor Oehler has published a significant number of articles and brings a vast amount of expertise to this position.

Project: Autoantibody Biomarkers for Ovarian Cancer Detection

Professor Peter Hoffmann

Strand Leader & Lloyd Sansom Chair in Biomaterials Engineering and Nanomedicine, Future Industries Institute, University of South Australia

A renowned expert in the large scale study of proteins (Proteomics) and tissue imaging mass spectrometry, Professor Peter Hoffmann is the strand leader in Biomaterials Engineering and Nanomedicine at University of South Australia’s Future Industries Institute.

With more than 90 papers published and almost $10 million raised for research, Professor Hoffmann’s area of expertise is focussed on biomarker discovery in cancer, detection of protein phosphorylation and Tissue Imaging Mass Spectrometry.

Professor Hoffmann’s research team were the first to use and publish Imaging Mass Spectrometry (IMS) techniques in Australia, techniques that are used to investigate protein and peptide distributions in human tissue.

More recently Professor Hoffmann formed the spin out company Onco DX to commercialise patented biomarkers for the early detection of ovarian and gastric cancers.

Professor Hoffmann is also Director of the National NCRIS facility for Tissue Imaging Mass Spectrometry.

Project: Autoantibody Biomarkers for Ovarian Cancer Detection

Dr Noor Lokman

Postdoctoral Fellow, Adelaide Medical School, University of Adelaide

Dr Lokman is a research fellow in the Reproductive Cancer group in the Discipline of Obstetrics and Gynaecology, Adelaide University. Noor recently completed her PhD on the role of annexin A2 in ovarian cancer metastasis with Dr Carmela Ricciardelli and Professor Martin Oehler. She has developed a chick chorioallantoic membrane (CAM) model to study ovarian cancer invasion in vivo during her PhD studies. Her research is focused on characterising novel proteins involved in ovarian cancer metastasis and investigate the functional roles of these proteins in ovarian cancer metastasis. She also is investigating whether these novel proteins could be used as novel diagnostic and prognostic markers for ovarian cancer.

Project: Autoantibody Biomarkers for Ovarian Cancer Detection

Dr Kristina Warton

Senior Research Fellow, School of Women’s and Children’s Health, University of New South Wales

Dr Kristina Warton was awarded her PhD from the University of New South Wales in Sydney, Australia in 2002.  She undertook her first postdoctoral position at the Centre for Immunology at St Vincent’s Hospital in Sydney, where her work with the then-new technology of gene expression microarrays led to the identification of a novel gene family involved in inflammation. Dr Warton then went on to work in the biotech industry. Her most recent project was to characterise the genome-wide methylation changes in cell-free DNA of blood plasma from ovarian cancer patients, with the intent of creating a blood test for ovarian cancer based on the identified changes. In order to make this project successful, the group paid particular attention to quality control at each step of the protocol, and modified existing methods so that they could be applied to the challenging clinical specimens they were working with. The methods-oriented research paper describing the above work was accessed over 4000 times in the 12 months following publication. The differentially methylated regions found in that project are currently being developed into sensitive PCR assays that will identify blood samples from ovarian cancer patients.

Project: Methylated Circulating DNA in Blood for the Early Diagnosis of Ovarian Cancer

Associate Professor Michelle Hill

Head of Precision and Systems Biomedicine Laboratory, QIMR Berghofer Medical Research Institute

A/Professor Hill’s research began a new chapter at the QIMR Berghofer Medical Research Institute in April, 2017. As head of the Precision and Systems Biomedicine Laboratory, she aims to improve health outcomes by harnessing the power of omics and computational systems biology, and translating the findings to better clinical tests.

Her team is currently working to develop blood tests for early cancer detection, and to understand why obesity contributes to diseases such as cancer and neurodegeneration, in order to develop prevention strategies.

Associate Professor Hill obtained her PhD at the University of Queensland then under took postdoctoral work in Switzerland, Ireland, and back at University of Queensland. Her research training focussed on various aspects of cell signalling and membrane microdomain function using techniques in biochemistry, cell biology and subcellular proteomics.

With a passion for translational research, she established the Cancer Proteomics Group at the University of Queensland Diamantina Institute on the Princess Alexandra Hospital campus, Brisbane, Australia in 2009. Through interdisciplinary collaborations, the group has successfully developed a laboratory test for amyloidosis subtyping, and discovered serum biomarkers for oesophageal cancer.

Project: Discovery of New Blood Protein Biomarkers for Early Detection of Ovarian Cancer

Dr Andrew N Stephens

Research Group Head, Ovarian Cancer Biomarkers Laboratory, Hudson Institute of Medical Research

Dr Andrew Stephens is Head of the OCRF funded Ovarian Cancer Biomarkers Laboratory at the Hudson Institute of Medical Research. He provides leadership to the team and oversees the group’s research activities, aimed at the development of new diagnostic and therapeutic technologies for the early detection of ovarian cancer. He has substantial experience in the application of proteomic technologies to the discovery of new disease markers.

Dr Stephens completed his PhD in the department of Biochemistry at Monash University Australia. He held postdoctoral positions at the University of Sydney and at the Hudson Institute of Medical Research prior to taking up the position of OCRF Fellow in 2006.

Project: Multiplex Active Ratio Test for the Detection of Early Stage Ovarian Cancer

Dr Maree Bilandzic

Senior Research Fellow, Hudson Institute of Medical Research

Dr Maree Bilandzic joined the Ovarian Cancer Biomarkers Laboratory at the Hudson Institute of Medical Research in 2015. With extensive experience in ovarian cancer research, Dr Bilandzic’s work is focused on the early events controlling the spread of ovarian cancer cells to local healthy tissues – the defining event in the cycle of ovarian cancer progression from early- to late-stage disease. The unique laboratory models developed by Dr Bilandzic allow these events to be examined in real time in the laboratory, providing new insight into how early cell-cell interactions dictate the ultimate course of disease progression.

Dr Bilandzic completed her PhD at Deakin University (2007), and her expertise adds a new dimension to the research team. Her ongoing work will facilitate further examination of early-stage tumour markers in ovarian cancer model systems, as well as identifying novel therapeutic targets for better disease management.

Project: Multiplex Active Ratio Test for the Detection of Early Stage Ovarian Cancer

Dr Carlos Salomon

Head of Exosome Biology Laboratory, Centre for Clinical Diagnostics, University of Queensland

Carlos leads the Exosome Biology Laboratory based at The University of Queensland located at the Centre for Clinical Diagnostics (CCD) within UQ Centre for Clinical Research (UQCCR). His research interests include extracellular vesicles, ovarian cancer, pregnancy, preeclampsia, preterm birth and maternal obesity in pregnancy and gestational diabetes mellitus. Currently, Carlos holds a senior Lions Medical Research Foundation Fellowship (2016-2020).
With a Bachelor in Biochemistry with Honours in Immunology from the University of Concepcion, Chile and a Ma

ters degree in Clinical Biochemistry and Immunology, Carlos was awarded his PhD from The Pontifical Catholic University of Chile in December 2012. He has completed studies at The University of Barcelona (Barcelona, Spain), The University of Texas Health Science Center at San Antonio (San Antonio, Texas, USA), and The University of Queensland (Brisbane, QLD, Australia) in Regulation of transport systems (2010), Placental function during pregnancy (2011), and Mass Spectrometry (2012), respectively.

As an author of more than 70 journal publications and over 115 abstracts during the period of 2011-2017, Carlos established and leads the Exome Biology Laboratory in which human exosomes can be isolated, characterised and their role elucidated to evaluate their clinical utility as biomarkers of disease and therapeutic interventions.

Project: Novel Strategies to Improve Outcomes of Patients with Ovarian Cancer via Nanomedicine

Dr Andrew Lai

Senior Research Assistant, Exosome Biology Laboratory, Centre for Clinical Diagnostics, University of Queensland

Andrew obtained a Bachelor of Science degree in 2008 (University of New South Wales, Sydney) before moving to Brisbane to complete a Masters of Biotechnology (Queensland university of Technology, Brisbane) in 2010. He was further awarded a Bachelor of Applied Science with first class honours (Queensland university of Technology) in 2011 for a project involving the generation of functional recombinant proteins for use as potential chronic wound therapeutics. Afterwards, he undertook a PhD at the Institute of Health and Biomedical Innovation located at Queensland University of Technology and was conferred in 2016 for the investigation of the generation of novel bispecific antibodies to inhibit key cell surface receptors integral for the growth and migration of tumour cells.

Andrew joined the Exosome Biology group in 2016 where he has been a co-author in 6 journal papers. His interest includes the specific isolation and characterisation of ovarian cancer exosome in the hopes of gaining a better understanding of the biology and translating this knowledge into potential new treatments.

Project: Novel Strategies to Improve Outcomes of Patients with Ovarian Cancer via Nanomedicine

Dr Sherry Wu

Head of Cancer Therapeutics Laboratory, School of Biomedical Sciences, University of Queensland

Dr Sherry Wu obtained her PhD from the University of Queensland. She then undertook the TRIUMPH postdoctoral translational research fellowship at M.D. Anderson Cancer Centre. She has strong knowledge in target discovery using large-scale experimental and patient databases, in vitro and in vivo validation models, nanotechnology, and molecular biology techniques for studying mechanisms of action and resistance. Her research focuses on: 1) Developing strategies to overcome immune suppression in ovarian and breast cancers; 2) Developing novel strategies to enhance patient survival in ovarian cancer; 3) Developing novel nanoparticle platforms for tumour-targeted delivery; and 4) Early detection of ovarian cancer.

Project: A Novel Approach to Harness the Immune System to Battle Ovarian Cancer

Dr Simon Chu

Research Group Head, Hormone Cancer Therapeutics Group, Hudson Institute of Medical Research

Dr Simon Chu completed his PhD at Hudson Institute of Medical Research in 2005. His studies focused on the roles of oestrogen receptors in the pathogenesis of ovarian granulosa cell tumours (GCT), an uncommon type of ovarian cancer. In particular, he identified how estrogen receptor signalling was affected by other important molecular signalling pathways. This led to discovering a role for another important protein (the X-linked inhibitor of Apoptosis Protein), that contributes to the pathogenesis of not only GCT, but also for the more common epithelial ovarian cancers (EOC). After gaining his PhD, Dr Chu continued his work at the Hudson Institute of Medical Research, further examining these important pathways with the aim of identifying new therapeutic targets to treat both GCT and EOC.

In 2007, Dr Chu left the Hudson Institute of Medical Research to take up a postdoctoral position at the Pasteur Institute (Cambodia Campus), where he began training as a molecular virologist, and helped develop a new molecular technique to investigate the incidence of exposure to avian influenza in the human population in that country.

On his return to Australia in April 2009, Dr Chu returned to the Hudson Institute of Medical Research as an OCRF Research Fellow. His work now focuses on investigating the underlying causes of both EOC and GCT. He is currently investigating an exciting potential combined therapeutic option for treating these cancers, which target two important biological pathways in the ovarian cancer cell. This presents a new targeted therapeutic approach for the treatment of ovarian cancer.

Project: Exploring New Therapeutic Options for Epithelial Ovarian Cancers and Ovarian Granulosa Cell Tumours

Ms Trang Nguyen

Research Assistant, Hormone Cancer Therapeutics Group, Hudson Institute of Medical Research

Ms Trang Nguyen completed her honours studies at the Hudson Institute of Medical Research and the Department of Biochemistry at Monash University in 2013. Her work focused on members of the transforming growth factor-beta superfamily and modulating their signalling as potential therapeutic applications in clinical settings. As part of Dr Simon Chu’s research team at the Hudson Institute of Medical Research, her role is to investigate a novel combination therapeutic approach for the treatment of epithelial ovarian cancers and ovarian granulosa cell tumours.

Project: Exploring New Therapeutic Options for Epithelial Ovarian Cancers and Ovarian Granulosa Cell Tumours